Search

Your search keyword '"Toulouse, Andrea"' showing total 36 results
Start Over Author "Toulouse, Andrea"
36 results on '"Toulouse, Andrea"'

1. Beam shaping elements for single photon sources based on 3D printed micro-optics

Author

Jimenez Carlos, Toulouse Andrea, and Herkommer Alois

Subjects
Physics, QC1-999
Abstract

Multiple researchers have explored the use of 3D printed micro-optical components as interfaces to quantum point emitters by considering different designs and configurations. Typically, these designs involve parametric structures optimized in combination with idealized point source models following the principles of imaging optics. In this work, we propose a different approach based on the use of well-known numerical routines developed in the field of illumination optics. We compare the obtained design to reference parametric 3D printed based interfaces, which have been used in the context of 3D printed micro-optical interfaces to single photon sources.

Published
2024
Full Text
View/download PDF

7. 3D Printing of Colored Micro-Optics

Author

Aslani, Valese, primary, Toulouse, Andrea, additional, Schmid, Michael, additional, Giessen, Harald, additional, Haist, Tobias, additional, and Herkommer, Alois, additional

Published
2023
Full Text
View/download PDF

8. 3D micro-printing of miniaturized fiber-optic probes capable of multi-modal imaging and beam tailoring

Author

Li, Jiawen, primary, Thiele, Simon, additional, Ruchka, Paul, additional, Toulouse, Andrea, additional, Kirk, Rodney W., additional, Quirk, Bryden C., additional, Hoogendoorn, Ayla, additional, Chen, Yungchin, additional, Peter, Karlheinz, additional, Nicholls, Stephen J., additional, Verjans, Johan, additional, Psaltis, Peter J., additional, Bursill, Christina, additional, Herkommer, Alois M., additional, Giessen, Harald, additional, and McLaughlin, Robert A., additional

Published
2023
Full Text
View/download PDF

9. 3D Direct Laser Writing of Highly Absorptive Photoresist for Miniature Optical Apertures.

Author

Schmid, Michael D., Toulouse, Andrea, Thiele, Simon, Mangold, Simon, Herkommer, Alois M., and Giessen, Harald

Subjects
*OPTICAL elements, *PHOTORESISTS, *OPTICAL devices, *LASERS, *MICRO-optics, *OPTICAL apertures, *DIFFRACTIVE optical elements
Abstract

The importance of 3D direct laser writing as an enabling technology increased rapidly in recent years. Complex micro‐optics and optical devices with various functionalities are now feasible. Different possibilities to increase the optical performance are demonstrated, for example, multi‐lens objectives, a combination of different photoresists, or diffractive optical elements. It is still challenging to create fitting apertures for these micro optics. In this work, a novel and simple way to create 3D‐printed opaque structures with a highly absorptive photoresist is introduced, which can be used to fabricate microscopic apertures increasing the contrast of 3D‐printed micro optics and enabling new optical designs. Both hybrid printing by combining clear and opaque resists, as well as printing transparent optical elements and their surrounding opaque apertures solely from a single black resist by using different printing thicknesses are demonstrated. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Trial in progress: Durvalumab and olaparib for the treatment of prostate cancer in men predicted to have a high neoantigen load.

Author

Sokolova, Alexandra, primary, Gulati, Roman, additional, Cheng, Heather H., additional, Beer, Tomasz M., additional, Graff, Julie N, additional, Amador, Melanie, additional, Toulouse, Andrea, additional, Taylor, Kamilah, additional, Bailey, Shawna, additional, Smith, Steven, additional, Tabatabaei, Shaadi, additional, Sinit, Ryan, additional, Slottke, Rachel, additional, Vuky, Jacqueline, additional, Yezefski, Todd, additional, Grivas, Petros, additional, Yu, Evan Y., additional, and Schweizer, Michael Thomas, additional

Published
2022
Full Text
View/download PDF

18. The fluciclovine (FACBC) PET/CT site-directed therapy of oligometastatic prostate cancer (Flu-BLAST-PC) trial.

Author

Wong, Risa Liang, primary, Holt, Sarah K, additional, Zeng, Jing, additional, Graham, Laura, additional, Kang, Rachel, additional, Conrad, Nathan, additional, Toulouse, Andrea, additional, Bauer, Zoya, additional, Lai, Michael, additional, Yezefski, Todd, additional, Wright, Jonathan L., additional, Weg, Emily Steinberger, additional, Hsieh, Andrew Caleb, additional, Cheng, Heather H., additional, Lee, Jean H, additional, Chen, Delphine L., additional, Lin, Daniel W., additional, and Yu, Evan Y., additional

Published
2021
Full Text
View/download PDF

21. Use of 18F-fluciclovine PET/CT (FluPET) for prostate cancer (PC): Initial results from a prospective registry at a tertiary academic center.

Author

Wong, Risa Liang, primary, Cheng, Heather H., additional, Holt, Sarah K, additional, Conrad, Nathan, additional, Loesch, Hannah, additional, Fernandez, Sara, additional, Sahoo, Rameen, additional, Bauer, Zoya, additional, Toulouse, Andrea, additional, Grivas, Petros, additional, Yezefski, Todd, additional, Russell, Kenneth J., additional, Wright, Jonathan L., additional, Schweizer, Michael Thomas, additional, Montgomery, Robert B., additional, Lee, Jean H, additional, Chen, Delphine L., additional, Zeng, Jing, additional, Lin, Daniel W., additional, and Yu, Evan Y., additional

Published
2021
Full Text
View/download PDF

36. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

Author

Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, and Varga A

Subjects
Adult, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, B7-H1 Antigen immunology, Cohort Studies, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Kaplan-Meier Estimate, Middle Aged, Antibodies, Monoclonal, Humanized administration & dosage, B7-H1 Antigen biosynthesis, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms immunology
Abstract

Purpose The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1-positive, advanced solid tumor cohorts. Here, we present the results from the cohort of patients with advanced cervical cancer. Methods Patients were treated with pembrolizumab 10 mg/kg every 2 weeks for up to 24 months. Response was assessed every 8 weeks for the first 6 months and every 12 weeks thereafter. The primary end point was overall response rate per Response Evaluation Criteria in Solid Tumors, version 1.1, by investigator review. Safety was a secondary end point. Results Twenty-four patients were enrolled in the cervical cancer cohort. The median age was 42 years (range, 26 to 62 years), 22 patients (92%) had received prior radiation therapy, and 15 patients (63%) had received two or more lines of therapy, including bevacizumab (10 of 24 patients), for advanced disease. At the data cutoff, median follow-up duration was 11.0 months (range, 1.3 to 32.2 months). Overall response rate was 17% (95% CI, 5% to 37%); four patients (17%) achieved a confirmed partial response, and three patients (13%) had stable disease. Median duration of response for the four patients who achieved a partial response was 5.4 months (4.1 to 7.5 months). Treatment related adverse events (AEs) were experienced by 18 patients (75%); only rash (n = 5; 21%) and pyrexia (n = 4; 17%) and occurred in ≥ 10% of patients. Five patients experienced grade 3 treatment-related AEs. No grade 4 treatment-related AEs or deaths were observed. Conclusion In patients with programmed death ligand 1-positive advanced cervical cancer, pembrolizumab demonstrated antitumor activity and exhibited a safety profile consistent with that seen in other tumor types.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results